Order Information
Contact us
Insert title here
Featured Products
HY-10372  |  PP121
HY-10005  |  Flavopiridol
HY-10008  |  SNS-032
HY-10087  |  Navitoclax
HY-10161  |  Tozasertib
HY-10162  |  Olaparib
HY-10180  |  MLN8054
HY-10192  |  NVP-TAE 684
HY-10193  |  AZD-1480
HY-10249  |  GSK-690693
HY-10254  |  PD0325901
HY-10355  |  AKT inhibitor VIII
HY-10358  |  MK 2206 (dihydrochloride)
HY-10997  |  PCI-32765
HY-11001  |  PHA-793887
HY-11002  |  CP-466722
HY-11007  |  GNF-2
HY-30237  |  Roscovitine
HY-50662  |  A-769662
HY-50767  |  Palbociclib
Products |  Featured Products
Cat.No. Product Name / Activity Added
HY-10005 Flavopiridol September 2017
Flavopiridol is a broad inhibitor of <b>CDK</b>, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with <b>IC<sub>50</sub></b> of around 40 nM.
HY-10008 SNS-032 September 2017
SNS-032 is a selective inhibitor of?<b>cyclin-dependent kinase (CDK)</b>, inhibiting <b>CDK2/7/9</b> with?<b>IC<sub>50</sub></b>s?of 48 nM/62 nM/4 nM.
HY-10087 Navitoclax September 2017
Navitoclax is a potent and orally bioavailable <b>Bcl-2 family protein</b> inhibitor that binds with high affinity (<b>K<sub>i</sub></b> < 1 nM) to multiple anti-apoptotic Bcl-2 family proteins including Bcl-x<sub>L</sub>, Bcl-2 and Bcl-w.
HY-10161 Tozasertib September 2017
Tozasertib is the inhibitor of <b>Aurora-A, -B, -C kinases</b> with <b>K<sub>i</sub></b> values of 0.
HY-10162 Olaparib September 2017
Olaparib is a potent <b>PARP</b> inhibitor with <b>IC<sub>50</sub></b> of 5 and 1 nM for <b>PARP-1</b> and <b>PARP-2</b>, respectively.
HY-10180 MLN8054 September 2017
MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM; exhibits more than 40-fold selective for Aurora A than Aurora B.
HY-10192 NVP-TAE 684 September 2017
NVP-TAE 684 is a highly potent and selective <b>ALK</b> inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with <b>IC<sub>50</sub></b> values between 2 and 10 nM.
HY-10193 AZD-1480 September 2017
AZD-1480 is a novel ATP-competitive <b>JAK2</b> inhibitor with <b>IC<sub>50</sub></b> of 0.
HY-10249 GSK-690693 September 2017
GSK-690693 is a pan-Akt inhibitor targeting?<b>Akt1/2/3</b>?with?<b>IC<sub>50</sub></b>?of 2/13/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes.
HY-10254 PD0325901 September 2017
PD0325901 is a selective and non ATP-competitive <b>MEK</b> inhibitor with <b>IC<sub>50</sub></b> of 0.
HY-10355 AKT inhibitor VIII September 2017
AKT inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit <b>Akt1</b>, <b>Akt2</b>, and <b>Akt3</b> activity with <b>IC<sub>50</sub></b>s of 58 nM, 210 nM, and 2.
HY-10358 MK 2206 (dihydrochloride) September 2017
MK 2206 is an orally active allosteric <b>Akt</b> inhibitor with <b>IC<sub>50</sub></b> of 5 nM/12 nM/65 nM for <b>Akt1/2/3</b>, respectively.
HY-10372 PP121 September 2017
PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.
HY-10997 PCI-32765 September 2017
PCI-32765 is a selective, irreversible <b>Btk</b> inhibitor with <b>IC<sub>50</sub></b> value of 0.
HY-11001 PHA-793887 September 2017
PHA-793887 is a novel pan-cdk inhibitor, including cdk1, cdk2, cdk4, cdk5, cdk7, and cdk9 with IC50 in the 5 to 140 nM range.
  1 2  
Insert title here
Products are for research use only. Not for human use. We do not sell to patients.           Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China  
86-21-58998590   FAX: 86-21-53700326, 86-21-58998590   E-mail: sales@chemexpress.cn